Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0029-7844(02)01973-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Causes and outcomes of hepatic fibrosis in persons living with HIV.
Curr Opin HIV AIDS
November 2022
University of Cincinnati, College of Medicine, Cincinnati, USA.
Purpose Of Review: The epidemiology of liver disease in people living with HIV has evolved since the arrival of effective hepatitis C virus (HCV) treatment. Nonalcoholic fatty liver disease (NAFLD) in HIV patients is highly prevalent while hepatitis D, hepatitis E, and occult hepatitis B remain underappreciated. We discuss mechanisms of fibrosis in HIV and review clinical outcomes of HIV-associated liver diseases.
View Article and Find Full Text PDFHepatotoxicity of Contemporary Antiretroviral Drugs: A Review and Evaluation of Published Clinical Data.
Cells
May 2021
Division of Infectious Diseases, Mayo Clinic, Rochester, MN 55905, USA.
Contemporary antiretroviral agents afford enhanced potency and safety for patients living with HIV. Newer antiretroviral drugs are often better tolerated than those initially approved in the early stages of the HIV epidemic. While the safety profile has improved, adverse drug reactions still occur.
View Article and Find Full Text PDFEfavirenz-Induced Vanishing Bile Duct Syndrome: A Case Report.
J Pharm Pract
April 2021
Department of Medicine, Emory Decatur Hospital, Decatur, GA, USA.
Background: Efavirenz (Sustiva®) is used for the treatment of human immunodeficiency virus (HIV) type 1 infection. Hepatoxicity is a known potential adverse drug event with efavirenz; however, to our knowledge, vanishing bile duct syndrome (VBDS), a type of liver injury, has not been reported with this therapy.
Case Presentation: We report the case of a 48-year-old male with HIV and VBDS secondary to antiretroviral therapy.
Detecting spatial clusters of HIV and hepatitis coinfections.
PLoS One
March 2019
HIV/AIDS, Hepatitis, STD and TB Administration (HAHSTA), District of Columbia Department of Health, Government of the District of Columbia, Washington DC, United States of America.
Background: People with HIV infection in the United States are often affected by chronic viral hepatitis. These coinfected people with either HBV or HCV are at increased risk for serious, life-threatening complications. Coinfections with viral hepatitis may also complicate the delivery of anti-retroviral therapy (ART) by escalating the risk of drug-related hepatoxicity.
View Article and Find Full Text PDFPharmacokinetics and Safety Profile of Artesunate-Amodiaquine Coadministered with Antiretroviral Therapy in Malaria-Uninfected HIV-Positive Malawian Adults.
Antimicrob Agents Chemother
July 2018
Malawi College of Medicine, Blantyre, Malawi
There are limited data on the pharmacokinetic and safety profiles of artesunate-amodiaquine in human immnunodeficiency virus-infected (HIV) individuals receiving antiretroviral therapy. In a two-step intensive sampling pharmacokinetic trial, we compared the area under the concentration-time curve from 0 to 28 days (AUC) of an active metabolite of amodiaquine, desethylamodiaquine, and treatment-emergent adverse events between antiretroviral therapy-naive HIV adults and those taking nevirapine and ritonavir-boosted lopinavir-based antiretroviral therapy. In step 1, malaria-uninfected adults ( = 6/arm) received half the standard adult treatment regimen of artesunate-amodiaquine.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!